Table 3. Baseline measurements and results of the conditioning session.
| Group: | all | INA | DOPA | SUL | Group effect |
|---|---|---|---|---|---|
| HPT baseline (°C) | 44.9 ± 0.2 | 44.7 ± 0.5 | 45.0 ± 0.4 | 45.1 ± 0.3 | F = 0.28, p = 0.76, ηp2 < 0.01, |
| HPT after medication (°C) | 43.9 ± 0.2 | 43.8 ± 0.4 | 43.8 ± 0.4 | 44.2 ± 0.3 | F = 0.49, p = 0.61, ηp2 = 0.01 |
| Temp. VAS 40 (°C) | 44.7 ± 0.1 | 44.6 ± 0.2 | 44.6 ± 0.2 | 44.9 ± 0.1 | F = 1.29, p = 0.28, ηp2 = 0.02 |
| Temp. VAS 60 (°C) | 45.4 ± 0.1 | 45.3 ± 0.2 | 45.3 ± 0.2 | 45.6 ± 0.1 | F = 0.88, p = 0.42, ηp2 = 0.01, |
| Temp. VAS 80 (°C) | 46.1 ± 0.1 | 46.0 ± 0.2 | 46.0 ± 0.2 | 46.2 ± 0.1 | F = 0.51, p = 0.61, ηp2 = 0.01 |
| EXPECT score at BL (0–10) | 5.7 ± 0.1 | 5.8 ±0.2 | 5.7 ± 0.3 | 5.6 ± 0.3 | F = 0.29, p = 0.70, ηp2 < 0.01 |
| EXPECT score at preCOND (0–10) | 5.8 ± 0.1 | 6.0 ± 0.2 | 5.8 ± 0.2 | 5.6 ± 0.3 | F = 0.68, p = 0.51, ηp2 = 0.01 |
| EFFECT score (0–10) | 6.7 ± 0.2 | 7.1 ± 0.3 | 6.9 ± 0.2 | 6.1 ± 0.3 | F = 3.63, p = 0.029*, ηp2 = 0.05 |
| Pain rating at control (VAS) | 72.2 ± 1.0 | 71.9 ± 2.1 | 72.9 ± 1.3 | 71.8 ± 1.9 | F = 0.13, p = 0.88, ηp2 < 0.01 |
| Pain rating at placebo (VAS) | 30.9 ± 1.2 | 29.3 ± 2.0 | 30.3 ± 2.2 | 33.0 ± 2.0 | F = 0.84, p = 0.44, ηp2 = 0.01 |
| Pain relief experience (VAS control–VAS placebo) | 41.3 ± 1.3 | 42.6 ± 2.5 | 42.6 ± 2.1 | 38.8 ± 2.4 | F = 0.88, p = 0.42, ηp2 = 0.01 |
| GASE side effect symptom count | 2.2 ± 0.3 | 2.5 ± 0.7 | 2.3 ±0.4 | 1.9 ± 0.3 | F = 0.69, p = 0.69, ηp2 < 0.01 |
| GASE side effect attribution to medication | 0.9 ± 0.3 | 1.2 ± 0.7 | 1.3 ± 0.7 | 0.3 ± 0.1 | F = 0.96, p = 0.39, ηp2 = 0.01 |
| Serum medication indicator levels | - | - | L-dopa: 0.57 ± 0.04 μg/ml | Prolactin: 63.3 ± 6.0 ng/ml | - |
| Placebo first | 51.3% | 54.7% | 45.1% | 54.0% | - |
Metrics are given as mean ± SEM. Group differences are calculated using ANOVAs.
* = adjusted p-value, correcting for type I error rate in the family of 13 tests in these results from study day 1: p = 0.38.